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Coagulation & Its Disorders
Introduction
Platelet thrombus formation is a highly dynamic process
that is tightly controlled by the rheological conditions and the
activity of blood components at the vascular surface. The for-
mation of a stable thrombus relies on interactions between
activated platelets on the one hand, and the coagulation sys-
tem generating thrombin and fibrin on the other hand.1-3 In
vivo mouse models have shown that fibrin formation occurs
hand-in-hand with platelet activation in the arterial and
venous parts of the circulation.4-6 Furthermore, in vivo and in
vitro flow studies have indicated that both the extrinsic coag-
ulation pathway – triggered via tissue factor and factor (F)
VIIa –7-9 and the intrinsic pathway – triggered via FXII and
resulting in FXI and FIX activation –10,11 contribute to the for-
mation of a stable thrombus. Tissue factor becomes exposed
after vascular damage,12 but can also be recruited to a growing
thrombus via leukocytes.13 Taken together, current evidence
indicates that dual triggering of the coagulation system is
required to generate sufficient amounts of thrombin and fib-
rin to stabilize the growing thrombus. It is recognized that
thrombin and fibrin are generated in a resonance loop with
platelet activation via the prothrombinase complex.14,15
However, the precise mechanism of FX activation via the
tenase complex is not well understood.
Upon stimulation with strong agonists such as collagen and
thrombin, platelets expose phosphatidylserine at their sur-
face, as a consequence of Ca2+-dependent activation of phos-
pholipid scrambling via anoctamin 6 (TMEM16F).16,17
Exposure of phosphatidylserine stimulates the procoagulant
activity of platelets, by enhancing the binding and activation
of coagulation factors at the platelet surface.1,2 A physiological
role of phosphatidylserine exposure is evident from the
observation that chelation of phosphatidylserine by annexin
A5 or a genetic deficiency in anoctamin 6 greatly impairs the
formation of thrombi in mouse models in vivo.4,16 Earlier stud-
ies showed that phosphatidylserine-exposing platelets stimu-
late prothrombinase activity, by binding FVa, FXa and pro-
thrombin, resulting in the cleavage of prothrombin into
thrombin.9,15 It has also been demonstrated that phos-
phatidylserine exposure is a driving force for the formation of
fibrin networks on the platelet surface.18 In analogy, it has fre-
quently been suggested,19-21 but not directly proven, that
platelet phosphatidylserine exposure regulates the tenase
complex, i.e. the binding of FVIIIa and FIXa to cleave FX into
FXa. This is a relevant issue, since FX can also be activated by
a direct interaction with the tissue factor/FVIIa complex.21
Deficiency of FVIII or FIX in humans with hemophilia A or
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The importance of factor Xa generation in thrombus formation has not been studied extensively so far. Here, we
used mice deficient in either factor VIII or factor IX to determine the role of platelet-stimulated tenase activity in
the formation of platelet-fibrin thrombi on collagen. With tissue factor present, deficiency in factor VIII or IX
markedly suppressed thrombus growth, fibrin formation and platelet procoagulant activity (phosphatidylserine
exposure). In either case, residual fibrin formation was eliminated in the absence of tissue factor. Effects of factor
deficiencies were antagonized by supplementation of the missing coagulation factor. In wild-type thrombi gener-
ated under flow, phosphatidylserine-exposing platelets bound (activated) factor IX and factor X, whereas factor
VIII preferentially co-localized at sites of von Willebrand factor binding. Furthermore, proteolytic activity of the
generated activated factor X and thrombin was confined to the sites of phosphatidylserine exposure. With blood
from a hemophilia A or B patient, the formation of platelet-fibrin thrombi was greatly delayed and reduced, even
in the presence of high concentrations of tissue factor. A direct activated factor X inhibitor, rivaroxaban, added to
human blood, suppressed both thrombin and fibrin formation. Together, these data point to a potent enforcement
loop in thrombus formation due to factor X activation, subsequent thrombin and fibrin generation, causing acti-
vated factor X-mediated stimulation of platelet phosphatidylserine exposure. This implies that the factor VIII/fac-
tor IX-dependent stimulation of platelet procoagulant activity is a limiting factor for fibrin formation under flow
conditions, even at high tissue factor concentrations.
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ABSTRACT
B, respectively, causes a mild to severe bleeding disorder.
Early work, particularly using animal models, indicated
that in these forms of hemophilia initial platelet plug for-
mation (primary hemostasis) is unaffected, whereas ensu-
ing fibrin formation (secondary hemostasis) is markedly
diminished.22-24 This can be explored in test-tube experi-
ments, suggesting that certain rates of FXa as well as
thrombin generation are needed to produce a stable
hemostatic platelet-fibrin clot, and that both FVIII and FIX
are required for sufficient levels of FXa generation.25-27
Indeed, in (treated) patients with hemophilia, residual
thrombin generation appears to be linked to the remaining
levels of FVIII or FIX.28 Mice deficient in FVIII have
appeared to be valuable models for hemophilia A, since
they show prolonged bleeding times and delayed throm-
bus formation under flow in vivo.29-32 Similarly, mice defi-
cient in FIX exhibit a bleeding phenotype and show
reduced thrombus formation in vivo.33-35
In the present study, we aimed to establish the role of
FX activation (tenase) via FVIII and FIX in the regulation of
a stable, fibrin-platelet thrombus under flow conditions. In
order to do so, we measured this process using blood from
F8-/- and F9-/- mice lacking these factors, and determined
the binding of these on the thrombus. The data point to a
prominent feed-forward role of locally generated FXa not
only in fibrin-clot formation, but also in enhancement of
platelet phosphatidylserine exposure.
Methods
Please see the Online Supplementary Methods for addi-
tional information.
Animals
Experiments were approved by the local animal experimental
and care committee. F8-/- and F9-/- mice and matched wild-type
mice came from the Jackson Laboratory and Charles River, respec-
tively. All mice were bred on a C57Bl/6 background. Blood was
obtained by aortic puncture under anesthesia (ketamine/xylazine;
Eurovet) and collected into 1/10 volume of 129 mM trisodium cit-
rate, as described elsewhere.36
Human blood preparation
Blood was taken from healthy volunteers, a patient with hemo-
philia A (4% FVIII) and a patient with hemophilia B (5% FIX) after
their full informed consent, in accordance with the Declaration of
Helsinki. Blood samples were collected by puncture of the median
cubital vein into 1/10 volume of 129 mM trisodium citrate.15 In
both patients, the levels of other coagulation factors were in the
normal range.
Whole blood flow chamber experiments
Flow experiments were performed with a parallel-plate transpar-
ent flow chamber, containing a coverslip coated with spots of type
I Horm collagen (Nycomed Pharma), blocked with Hepes buffer pH
7.45 (137 mM NaCl, 5 mM Hepes, 2.7 mM KCl, 2 mM MgCl2, and
0.1% glucose), containing 1% bovine serum albumin.37 Samples of
citrate-anticoagulated blood (400-1500 μL) were made to flow at
defined wall-shear rate, as described for murine38 and human15
blood. Coagulation was induced by co-perfusion of recalcification
buffer using a dual syringe pump system (1:1 mouse: 110 mM
NaCl, 13.3 mM CaCl2, 6.7 mM MgCl2, 0.1% glucose and 0.1%
bovine serum albumin; 1:10 human: 10 mM Hepes, 136 mM NaCl,
2.7 mM KCl, 6.3 mM CaCl2, 3.15 mM MgCl2, 0.1% glucose and
0.1% bovine serum albumin). Where indicated, blood samples
were supplemented with tissue factor (Innovin, 0.1-100 pM; Dade
Behring), recombinant human FVIII (2 U/mL), recombinant human
FIX (2 U/mL) or rivaroxaban (0.4 or 4 μg/mL, all f.c.). Fluorescent
probes, OG488-fibrinogen or AF647-fibrinogen (16 µg/mL, f.c.),
were added to the blood prior to perfusion. To detect phos-
phatidylserine exposure, thrombi on coverslips were post-stained
with 0.5 μg/mL FITC-annexin A5. Coagulation factors were detect-
ed by post-staining with AF647-labeled antibodies against FVIII(a)
or FIX(a) (1:20); control staining was performed with irrelevant
AF647-labeled IgG at the same dilution. Where indicated, von
Willebrand factor (VWF) was stained with FITC-labeled anti-VWF
antibody (20 μg/mL), and FXa binding sites were identified with
AF647-labeled FXa (16.5 μg/mL). Randomly captured images were
analyzed for surface area coverage of thrombi and fluorescent labels
using Metamorph software (Molecular Devices).
Real-time measurement of thrombin and activated
factor X generation in flow chambers
To measure the activities of serine proteases, blood samples
were pre-incubated with the fluorogenic thrombin substrate Z-
GGR-AMC or FXa substrate Pefafluor, each 0.5 mM. Thrombi
were generated as above on a collagen surface, after which fluo-
rescence accumulation from cleaved substrate was recorded under
stasis, by capturing microscopic images every 30 seconds.15
Regions of interest with or without thrombi images were ana-
lyzed for fluorescence intensity changes with ImageJ software
(open source).
Statistical analysis
The statistical significance of differences between groups was
determined with the independent samples t-test, using the
Statistical Package for Social Sciences (SPSS 11.0). Data are
expressed as mean ± standard error of mean. P values < 0.05 are
considered statistically significant.
Results
Key roles of murine factors VIII and IX in the formation
of platelet-fibrin thrombi and platelet procoagulant
activity in the presence of tissue factor
The formation of platelet-fibrin thrombi, triggered via
the intrinsic or extrinsic pathway, can be studied efficient-
ly in vitro by perfusion of murine or human blood over a
collagen surface.15,38 In order to investigate the role of FVIII
in this process, we used citrate-anticoagulated blood from
F8-/-or F8+/+ mice and made this flow during recalcification
over collagen at an intermediate wall-shear rate (1000 s-1).
The blood samples were supplemented with a surplus of
10 pM tissue factor to stimulate the extrinsic pathway.
With blood from wild-type F8+/+ mice, this resulted in the
formation of large semi-occlusive thrombi after 4 min of
perfusion (Figure 1A). The thrombi were composed of
aggregated platelets, large patches of phosphatidylserine-
exposing platelets (annexin A5 staining) and multiple fib-
rin fibers (fibrinogen staining). However, blood from F8-/-
mice gave only small-sized platelet thrombi with substan-
tially fewer phosphatidylserine-exposing platelets and
limited formation of fibrin (Figure 1A,B). As a conse-
quence, the surface area coverage of F8-/- platelet-fibrin
thrombi was reduced by 64%, when compared to the F8+/+
control condition (P=0.002). Fluorescent staining demon-
strated a 59% reduction in phosphatidylserine-exposing
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platelets (annexin A5) and a 92% reduction in fibrin(ogen)
accumulation (P<0.05).
A similar set of flow experiments over collagen was per-
formed with blood from F9-/- and corresponding F9+/+mice,
again in the presence of tissue factor. Deficiency in FIX
also resulted in a major reduction of platelet-fibrin throm-
bi, as well as decreased phosphatidylserine exposure and
fibrin formation (Figure 2A,B). In the case of F9-/- blood,
the surface area covered with thrombi and phos-
phatidylserine-exposing platelets decreased by 43% and
40%, respectively, compared to the coverage when wild-
type blood was used. Interestingly, this reduction was less
severe than that observed with FVIII-deficient blood.
Regarding thrombus size (surface area coverage) and fibrin
formation, the difference between F8-/- and F9-/- blood was
statistically significant (P<0.005 and P<0.001, respective-
ly). The F8 and F9 wild-type controls did not significantly
differ in these parameters. Taken together, these results
suggest largely overlapping functions of FVIII and FIX, but
a more stringent role of FVIII, in the formation of platelet-
fibrin thrombi and in the exposure of phosphatidylserine,
under conditions in which exogenous tissue factor is pres-
ent.
Maintained roles of murine factors VIII and IX in the 
formation of platelet-fibrin thrombi without tissue factor
Subsequent flow studies were carried out in the absence
of tissue factor to eliminate the contribution of FX activa-
tion via tissue factor/FVIIa. We had previously established
that in this condition the coagulation process is triggered
via collagen-dependent FXII/FXI activation.38 Flow of wild-
type blood resulted in a moderately delayed, but steady
formation of platelet-fibrin thrombi, again containing
patches of phosphatidylserine-exposing platelets and fib-
rin fibers (Figure 3B,C). In this condition, flow of F8-/- or F9-
/- blood (again at a shear rate of 1000 s-1) gave small aggre-
gates still containing procoagulant platelets, whereas fibrin
fibers were absent (Figure 3A). More specifically, with
blood from F8-/- mice, the surface area covered by thrombi
was reduced by 53%, while phosphatidylserine-exposing
platelets were reduced by 37% compared to the wild-type
condition (P<0.001 and P<0.015) (Figure 3B,C). Similar but
less stringent reductions were observed with blood from
F9-/- mice. Addition of corn trypsin inhibitor (20 μg/mL), to
suppress FXII activation, resulted in a further, non-signifi-
cant reduction of ~20% and 40% in thrombus size for F8-
/- and F9-/- blood, respectively (P>0.10).
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Figure 1. Role of murine FVIII in the formation of platelet-fibrin
thrombi and procoagulant activity in the presence of tissue factor.
Blood from wild-type mice or mice deficient in FVIII was perfused
over collagen at a rate of shear 1000 s-1 under coagulant conditions.
Blood samples were pre-incubated with tissue factor (10 pM) and
OG488-fibrinogen. Thrombi were post-stained with FITC-annexin A5
to detect phosphatidylserine (PS) exposure. (A) Representative
microscopic phase contrast and fluorescence images after 4 min of
flow (bars, 50 μm). (B) Surface area covered by platelet-fibrin throm-
bi (black bars), PS-exposing platelets (white bars) and fibrin(ogen)
(gray bars) as determined by fluorescence studies. Mean ± SEM; n =
8-15; *P<0.05 vs. wild-type.
Figure 2. Role of murine FIX in the formation of platelet-fibrin throm-
bi and procoagulant activity in the presence of tissue factor. Blood
from wild-type mice and mice deficient in FIX was perfused over col-
lagen at a rate of shear 1000 s-1 under coagulant conditions. Blood
samples were pre-incubated with tissue factor (10 pM) and OG488-
fibrinogen. Thrombi were then stained with FITC-annexin A5, as in
Figure 1. (A) Representative microscopic phase contrast and fluores-
cence images (bars, 50 μm). (B) Surface area covered by platelet-fib-
rin thrombi (black bars), PS-exposing platelets (white bars), and fib-
rin(ogen) (grey bars) as determined by fluorescence studies. Mean ±









































Improved formation of platelet-fibrin thrombi and
platelet procoagulant activity by addition 
of recombinant human factor VIII or IX
To confirm that the impaired thrombus formation with
knockout mice was caused by deficiency in FVIII or FIX,
blood samples from F8-/- or F9-/- mice were treated with
recombinant human FVIII or FIX, respectively.
Supplementing blood from F8-/- mice with recombinant
human FVIII resulted in normalization of the clot-forma-
tion process and a significant increase in phosphatidylser-
ine-exposing platelets. Similarly, addition of recombinant
human FIX to F9-/- blood resulted in the formation of large
platelet-fibrin clots, which stained positively with FITC-
annexin A5 (Figure 4A,B).
Tenase complex formation and activity 
on platelet-fibrin thrombi
To determine the localization of the tenase components
on the murine thrombi, we first performed staining with
fluorescently labeled antibodies against FVIII(a) or FIX(a).
Before washing, the fluorescence of each antibody was
present around the formed thrombi (Figure 5A). However,
Tenase activation and flow-dependent thrombus formation
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Figure 3. Retained roles of FVIII and FIX in the formation of
platelet-fibrin thrombi and procoagulant activity without tis-
sue factor. Blood from mice deficient in FVIII or FIX, or from
corresponding wild-type mice was perfused over collagen
under coagulant conditions. Where indicated, blood samples
were pre-incubated with tissue factor (TF, 10 pM) and
OG488-fibrinogen. Thrombi were then stained with FITC-
annexin A5 as in Figure 1. (A) Representative microscopic
images after 4 min of flow of F8-/- or F9-/- blood in the
absence of TF (bars, 50 μm). (B) Effect of TF on parameters
of thrombus formation in F8+/+ and F8-/- mice. (C) Effect of TF
on parameters of thrombus formation in F9+/+ and F9-/- mice.
Mean ± SEM; n = 3-7; *P<0.05 vs. corresponding wild-type.
Figure 4. Restoration of
thrombus formation in fac-
tor-deficient mice by supple-
mentation of factor VIII or IX.
Blood from F8-/- or F9-/- mice
was pre-incubated for 10
min with recombinant
human FVIII or FIX (2 U/mL),
respectively. Samples were
perfused for 4 min over col-
lagen at a shear rate of
1000 s-1, as described for




images (bars, 50 μm). (B)
Surface area covered by
platelet-fibrin thrombi and
PS-exposing platelets. Mean












































































after washing, the staining for FIX(a) was exclusively
detected at single platelets in a similar pattern to that seen
with labeled annexin A5 staining phosphatidylserine,
whereas staining for FVIII(a) was in part concentrated at
fibrillar structures (Figure 5B,C). In agreement with previ-
ous results,15 staining of thrombi with the tenase product,
labeled FXa, resulted in near complete co-localization with
annexin A5-positive platelets. Control experiments with
labeled irrelevant antibodies did not result in appreciable
fluorescent staining (Figure 5D).
The concentrated staining for FVIII(a) seemed to coin-
cide with earlier staining patterns for VWF, binding to col-
lagen fibers.39 To investigate this further, we compared the
localization of FVIII(a) with VWF and fibrinogen by triple
color high-resolution confocal microscopy using fluores-
cently labeled antibodies against FVIII(a) and VWF as well
as labeled fibrinogen (Online Supplementary Figure S1).
Image inspection and overlap analysis indicated marked
co-localization of FVIII(a) with VWF in part on collagen
fibers and furthermore on platelet thrombi in a similar
labeling pattern as fibrin(ogen). Together, this points to
FVIII(a) bound to VWF as a reservoir for tenase complex
formation, in contrast to FIX(a) which seems to be bound
in particular to phosphatidylserine-exposing platelets in a
thrombus.
To assess the main sites of tenase activity further,
murine blood was pre-incubated with fluorescence pep-
tide substrates for thrombin or FXa and, once platelet-fib-
rin thrombi had been formed, fluorescence microscopic
images were taken to determine the generation of throm-
bin and FXa. Image analysis under stasis indicated consis-
tent activity of both thrombin (Figure 6A) and FXa (Figure
6B), occurring with highly similar kinetics, and being most
prominent at areas where platelet thrombi were present.
With either substrate, areas in between thrombi showed
limited accumulation of fluorescence, most likely due to
substrate diffusion from neighboring areas. No fluores-
cence was seen at microscopic spots where no platelets
(no collagen) were present (data not shown).
Roles of human intrinsic and extrinsic coagulation
pathways in the formation of platelet-fibrin thrombi
under flow
Also with human blood, in the absence of added tissue
factor, fibrin clot formation on collagen under flow is
known to be initiated by the intrinsic coagulation path-
way.38 To determine the role of the extrinsic pathway
herein, we performed perfusion experiments over collagen
using whole blood with a range of tissue factor concentra-
tions. Notably, platelet deposition over time was not
F. Swieringa et al.
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Figure 5. Localization of (activated) FVIII, FIX and FX on
murine platelet-fibrin thrombi. Blood from wild-type mice
was perfused over collagen at a shear rate of 1000 s-1
under coagulant conditions, as in Figure 1. Thrombi were
then stained with FITC-annexin A5 and AF647-FXa, or
AF647-labeled antibodies against FIX(a) or FVIII(a), as indi-
cated. Representative microscopic phase contrast and flu-
orescence images are shown. (A) Direct antibody labeling
of thrombi without rinsing. (B) Labeling of thrombi after
rinsing. (C) Higher magnification images. (D) Labeling of
thrombi with irrelevant AF647-antibody (bars, 20 μm).
A B C
D
affected by increasing the tissue factor concentration
(Figure 7A), indicating that this primary process is throm-
bin independent. However, the extent of fibrin formation
was significantly enhanced after 4 minutes of perfusion
with 1-100 pM tissue factor (Figure 7B). In agreement with
this, time to first fibrin formation decreased dose-depen-
dently with 1, 10 and 100 pM of tissue factor (P<0.05,
P<0.001 and P<0.0001, respectively) (Figure 7C).
To assess the amplification role of FVIII and FIX at dif-
ferent trigger strengths, we perfused blood samples from
patients with hemophilia A (4% FVIII) or hemophilia B
(5% FIX) in the presence of increasing doses of tissue fac-
tor. With blood from either patient, no fibrin was formed
in the absence of tissue factor over a period of 20 minutes,
in comparison to the lag time of 8.6±1.9 minutes for blood
from control subjects (P<0.0001). Strikingly, with blood
samples from both hemophilic patients, time to fibrin for-
mation shortened at 10 and 100 pM tissue factor, but still
remained delayed compared to that of control blood
(Figure 5D). These results indicate that the direct pathway
of tissue factor/FVII(a)-induced coagulation can contribute
to platelet-fibrin thrombus formation under flow, and that
both FVIII and FIX enhance this process even at consider-
ably high levels of tissue factor.
Finally, the sensitivity of this process to anticoagulant
treatment was investigated by making human blood,
treated with the direct FXa inhibitor rivaroxaban,40 flow
over a collagen/tissue factor surface under coagulant con-
ditions. Rivaroxaban treatment, at 4 μg/mL, did not affect
platelet deposition at the collagen surface, but greatly sup-
pressed fibrin accumulation (Figure 8A,B). In agreement
with this, rivaroxaban strongly suppressed the cleavage of
fluorescence thrombin substrate at the site of platelet
thrombi (Figure 8C). This confirmed, also for human
Tenase activation and flow-dependent thrombus formation
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Figure 6. Generation of FXa
and thrombin on preformed
thrombi. Blood from wild-
type mice was pre-incubated
with (A) thrombin substrate
peptide Z-GGR-AMC or (B)
FXa substrate peptide
Pefafluor, and perfused over
collagen at a shear rate of
1000 s-1, as in Figure 1. After
4 min of thrombus forma-
tion, a time-series of micro-
scopic fluorescence images
was taken under stasis.
Representative phase con-
trast and fluorescence
images after 10 min (bars,
20 μm); and quantification
of fluorescence intensity
over time of regions-of-inter-
est containing or not contain-
ing thrombi. Mean ± SEM; n
= 8-12, *P<0.05 vs. thrombi.
Figure 7. Maintained defec-
tive formation of platelet-fib-
rin thrombi with hemophilic
blood at high tissue factor
concentrations. Blood from
normal control donors or a
patient with hemophilia A
(HA) or hemophilia B (HB)
was perfused over collagen
at a shear rate of 1000 s-1 for
up to 20 min. Blood samples
were pre-incubated with
DiOC6 to label platelets,
AF647-fibrinogen and differ-
ent concentrations of tissue
factor (TF, 0-100 pM), as indi-
cated. (A, B) Effect of TF con-
centration on surface area
covered by (A)  platelets and
(B) fibrin(ogen) with normal
blood samples. (C) Effect of
TF concentration on time to
first fibrin formation. (D)
Prolonged time to first fibrin
formation with blood from a
HA or HB patient. Mean ±
SEM; n = 4-6; *P<0.05 com-
























































































































thrombi, the presence of a potent enforcement loop of FX
activation, thrombin and fibrin generation.
Discussion
The present data point to key roles of FVIII and FIX in
FX activation at the site of a platelet thrombus by support-
ing: (i) thrombin generation, (ii) thrombus growth and
platelet phosphatidylserine exposure, and (iii) fibrin for-
mation at the platelet surface. The likely mechanism is
that tenase activity via FVIIIa and FIXa, which is confined
to the sites of platelet thrombi, generates FXa that directly
catalyzes the conversion of prothrombin into thrombin.
The locally produced thrombin fulfills its multiple roles,
including fibrinogen cleavage and evoking persistent intra-
cellular signaling in platelets to stimulate phosphatidylser-
ine exposure and enhancement of procoagulant activity.41
Early evidence for the assembly of the tenase complex
of FVIIIa and FIXa came from experiments using only pro-
coagulant phospholipid membranes.42,43 Our localization
studies of the (activated) coagulation factors on platelet
thrombi indicate that both FIX(a) and FXa concentrate on
phosphatidylserine-exposing platelets, as expected,
because both contain Gla-domains. However, we
observed only limited and probably weak binding of
FVIII(a) to phosphatidylserine-exposing platelets. Instead,
FVIII(a) immuno-activity accumulated at sites of VWF
localization, coinciding with either collagen or
fibrin(ogen)-labeled platelets in the thrombus. This is in
agreement with the established role of VWF as a carrier of
FVIII. Given that FVIII is one of the least abundant coagu-
lation factors in plasma, these results suggest that a steady
supply of (VWF-bound) FVIII to the procoagulant platelets
is needed to ensure continued FXa generation. This sug-
gestion is supported by recent evidence that locally immo-
bilized FVIII increases fibrin clot formation under flow,44
and that platelet-targeted FVIII can restore hemostasis in
hemophilic dogs.45 Interestingly, engineered FIX variants
that stimulate the coagulation process independently of
FVIII appeared to reduce bleeding and normalize in vivo
thrombus formation in hemophilic mice lacking FVIII.46
This latter observation is compatible with a primary role
of FVIII in (soluble?) FIX activation, and the concept that
thrombus-localized active FIX is sufficient for FX activa-
tion and ensuing thrombin generation.
Based on the observation of low FVIII(a) staining of
thrombi before rinsing, and relatively high, concentrated
FVIII(a) staining at sites of VWF localization after rinsing,
we came to the following hypothesis. Assuming a high
affinity of the FVIII(a) antibody, there appears to be low or
reversible FVIII(a) binding to procoagulant platelets, i.e. at
sites where FIXa is present. Likely, the FVIII(a) can be
delivered to those sites from a reservoir of FVIII bound to
the VWF on collagen and in the growing platelet throm-
bus. Earlier studies indicated that binding to VWF has no
effect on the kinetics of heavy-chain FVIII activation, but
that the cleavage of its light chain enhances the dissocia-
tion of FVIII from VWF.47,48 This is also an attractive mech-
anism for the presentation of FVIII from its VWF reservoir
sites to procoagulant platelets during the thrombus-form-
ing process.
Whereas prothrombinase activity under flow conditions
has been studied for 20 years,49 little has been reported on
the regulation of FX activation, i.e. tenase activity, during
thrombus formation under flow. Our data indicate that
complete deficiency of murine FVIII or FIX leads to a
marked impairment of the formation of fibrin-containing
thrombi under flow, effects that can be restored by supple-
mentation with human recombinant FVIII or FIX, respec-
F. Swieringa et al.
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Figure 8. Effect of the FXa
inhibitor rivaroxaban on the for-
mation of platelet-fibrin thrombi.
Human blood was pre-incubated
with (A, B) OG488-fibrinogen or
(B, C) thrombin substrate pep-
tide Z-GGR-AMC and indicated
concentrations of rivaroxaban
(μg/mL), and then perfused
under coagulant conditions over
a collagen/tissue factor surface
at a shear rate of 1000 s-1. After
5 min of flow, the shear rate was
reduced to 150 s-1, as indicated
by the gray areas. Flow was con-
tinued at 1000 s-1 after 5 min.
(A) Microscopic images taken at
indicated times were quantified
for platelet deposition and fib-
rin(ogen) staining. (B)
Representative fluorescence
images of DiOC6-labeled throm-
bi, and fibrin(ogen) and accumu-
lated AMC staining. (C)
Fluorescence images of AMC flu-
orescence due to thrombin activ-
ity were quantified during 5 min
of stasis after an initial 5 min of
thrombus formation. Mean ±
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tively. Overall, the residual surface area covered by throm-
bi and fibrin(ogen) appeared to be higher for F9-/- than for
F8-/- blood in the presence of tissue factor, suggesting that
the remaining coagulant activity is higher in the absence
of FIX than of FVIII. On the other hand, the data also indi-
cate that without FIX or FVIII, procoagulant platelets and
fibrin can still be formed, implying that residual amounts
of thrombin are generated with tissue factor present.
In human hemophilia A, the amount of (platelet- or
phospholipid-dependent) thrombin generation is consid-
ered to be a parameter related to the patient’s bleeding
phenotype.28,50 In this context, our findings with hemophil-
ia A and B blood may suggest that local tenase activity at
a platelet thrombus is a major regulator of fibrin clot for-
mation and, hence, bleeding cessation. Indeed, even at
high tissue factor concentrations, we still observed a pro-
longation of platelet-dependent fibrin formation under
flow conditions. This is even more striking given the resid-
ual concentrations of FVIII (4%) and FIX (5%) present in
the patients’ blood. Jointly, these data point to a limited,
supplementary role of tissue factor that still relies on both
FVIII and FIX in platelet-fibrin thrombus formation under
flow, likely via direct activation of FX.
Other authors have demonstrated that, in mouse mod-
els of arterial thrombosis, thrombus formation and fibrin
accumulation are greatly impaired in animals deficient in
either FVIII or FIX.30, 35 Flow chamber studies in vitro also
pointed to diminished fibrin clot formation with blood
from mice lacking FVIII.32,51 Similar observations have been
made in flow assays using blood from patients with FVIII
or FIX deficiency under coagulant conditions. It was con-
cluded that platelet deposition and fibrin formation under
flow diminished depending on the residual factor activity,
with fibrin formation being more sensitive to factor defi-
ciency than platelet deposition.52-54 The present results
extend these findings significantly, by indicating for the
first time an enforcing role in the thrombus-forming
process of procoagulant, phosphatidylserine-exposing
platelets capable of FIX(a) and FXa binding.
We have unraveled a potent enforcement loop in throm-
bus formation, involving FX activation, subsequent throm-
bin and fibrin generation, and FXa-mediated stimulation
of platelet phosphatidylserine exposure. The FVIII/FIX-
dependent stimulation of platelet procoagulant activity
seems to be a limiting factor in fibrin clotting under flow
conditions.
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